MENU
+Compare
PRME
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$1.32
Change
-$0.10 (-7.04%)
Capitalization
186.25M

PRME Prime Medicine Forecast, Technical & Fundamental Analysis

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing... Show more

PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PRME with price predictions
May 07, 2025

PRME in downward trend: price expected to drop as it breaks its higher Bollinger Band on April 23, 2025

PRME broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 14 similar instances where the stock broke above the upper band. In of the 14 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PRME entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRME's RSI Oscillator exited the oversold zone, of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for PRME just turned positive on April 21, 2025. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in of 23 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in of 124 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.139) is normal, around the industry mean (14.238). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (252.967).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PRME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PRME is expected to report earnings to rise 41.94% to -43 cents per share on May 09

Prime Medicine PRME Stock Earnings Reports
Q1'25
Est.
$-0.44
Q4'24
Beat
by $0.18
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.03
Q1'24
Beat
by $0.07
The last earnings report on February 28 showed earnings per share of -31 cents, beating the estimate of -49 cents. With 2.30M shares outstanding, the current market capitalization sits at 186.25M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
21 Erie Street
Phone
+1 617 564-0013
Employees
234
Web
https://www.primemedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTCEX12.59N/A
N/A
Fidelity Advisor Total Intl Equity C
BCEGX20.77N/A
N/A
Sterling Capital Equity Income C
FSSFX9.58N/A
N/A
Fidelity Advisor Series Small Cap
RSMRX14.50N/A
N/A
RBC SMID Cap Growth R6
JFNSX61.30-0.43
-0.70%
Janus Henderson Global Life Sciences S

PRME and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-7.04%
CRSP - PRME
65%
Loosely correlated
+5.52%
BEAM - PRME
60%
Loosely correlated
+6.32%
RXRX - PRME
59%
Loosely correlated
+4.77%
NTLA - PRME
57%
Loosely correlated
+13.58%
CCCC - PRME
54%
Loosely correlated
+2.67%
More